本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Viking Therapeutics, Inc.

40.76
+0.15500.38%
成交量:388.46万
成交额:1.61亿
市值:46.07亿
市盈率:-19.23
高:43.15
开:42.09
低:40.01
收:40.60
52周最高:62.50
52周最低:18.92
股本:1.13亿
流通股本:1.10亿
量比:1.67
换手率:3.53%
股息:- -
股息率:- -
每股收益(TTM):-2.1195
每股收益(LYR):-1.0085
净资产收益率:-29.23%
总资产收益率:-20.48%
市净率:6.46
市盈率(LYR):-40.41

数据加载中...

2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

关联方拟减持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 拟减持2000股,总价约13.73万美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

关联方拟减持公告

Form 144 | Viking Therapeutics高管Greg Zante拟减持131687股,总价约1028万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 拟减持11000股,总价约88.94万美元
2024/10/25

关联方拟减持公告

Form 144 | Viking Therapeutics董事 Singleton拟减持16000股,总价约127万美元
2024/10/23

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Greg Zante拟减持16136股,总价约92.2万美元